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Horse fetal gonadal tissue was incubated with 3/?-hydroxy-5,7-pregnadien-20-one a d 5,7-cholestadien3fi- 
01 and it was shown that both substrates were converted to 3jShydroxy-5,7-androstadien-17-one. These 
findings support the proposal that in this tissue there is a 5,7-diene pathway producing 3B-hydroxy-5,7- 
androstadien-17-one, the putative precursor of equilin in the placenta. 
Equilin Horse Fetal gonad 3/S- Hydroxy-5. ?-androstadien- I Fone 
3~-Hydro~y-S,7-pregnadien-2~-one 5,7-Cholestadien-3~-o~ 
1. INTRODUCTION 
The blood and urine of pregnant mares contain 
high concentrations of estrogens, such as estrone 
(I), and also ring B unsaturated estrogens, such as 
equilin (II). The horse fetal gonad provides sub- 
strates for estrogen formation in the placenta [1,2]. 
It contains the steroidal 5,7-dienes, 3,&hydroxy- 
5,7-pregnadien-20-one (III) and 3.&hydroxy-5,7- 
androstadien-17-one (IV) as endogenous com- 
pounds [3] and can biosynthesise them from tri- 
tiated sodium acetate in vitro [4,5]. 3,&Hydroxy- 
5,7-pregnadien-20-one (III) has been proposed as 
the biosynthetic precursor of 3,8-hydroxy-5,7- 
androstadien-17-one (IV}, this compound being 
aromatised in the placenta to give equilin [4,5]. 3@- 
Hydroxy-5,7-androstadien-17-one couId also be 
the precursor of 3~-hydroxy-5,7,9-estratrien-17- 
one (V) 161. 
This report describes the in vitro conversion of 
5,7-cholestadien-3,8-ol (VI) to 3,&hydroxy-5,7- 
pregnadien-20-one and of the latter to 3,&hydroxy- 
5,7-androstadien-17-one by the horse fetal gonad. 
The structures of the above compounds are given 
in scheme 1. 
Scheme 1. (I) Estrone, (II) 3-hydroxy-1,3,5(10),7-estra- 
tetraen-17-one, (III) 3,&hydroxy-5,7-pregnadien-20-one, 
(IV) 3&hydroxy-5,7-androstadien-17-one, (V) 3#L 
hydroxy-5,7,9-estratrien-17-one, (VI) 5,7_cholestadien- 
3&01. 
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2. EXPERIMENTAL 
High performance liquid chromatography 
(HPLC) was carried out on a Waters radial com- 
pression C-18, 10 PM column. Thin-layer chroma- 
tography (TLC) was carried out on 0.30 mm layers 
of silicagel HF 2541366 (Merck). The solvent 
systems used were: petroleum ether (b.p. 60-8O”C)- 
ethyl acetate ((A) 9 : 1, v/v); cyclohexane-acetone 
((B) 3 :2, v/v; (C) 2: 1, v/v; (D) 4: 1, v/v). Pro- 
cedures for acetylation and hydrolysis of steroids 
were as described in [7]. 3,&Hydroxy-5,7-andro- 
stadien-17-one (IV) and 3,&hydroxy-5,7-pregna- 
dien-20-one (III) were synthesised as in [8]. 
3,&Hydroxy-5,7-[4-‘4C]pregnadien-20-one(spec. 
act. 2 GBq/mmol) was synthesised from [4-14C]- 
pregnenolone acetate [8]. The product was purified 
by TLC in system A followed by HPLC, the 
mobile phase being 15% water in methanol, flow 
rate 2 ml/min. Retention times were 10.5 and 
13.5 min for 3,&-hydroxy-5,7-pregnadien-20-one 
and pregnenolone acetates, respectively. The 3/3- 
hydroxy-5,7-[4-‘4C]pregnadien-20-one ac tate was 
hydrolysed and the free steroid purified by TLC in 
system C. 
5,7-[la,2cY(n)-3H]Cholestadien-3,&ol (VI) (spec. 
act. 35.7 GBq/mmol) was synthesised from 
[ la,2&r)-3H]cholesterol acetate [8]. The product 
was purified by TLC in benzene followed by 
HPLC, the mobile phase being methanol, flow 
rate 2 ml/min. Retention times were 18.5 and 
22.25 min for 5,7-cholestadien-3@-ol and choles- 
terol acetates, respectively. The 5,7-[h.~,20(n)-~H]- 
cholestadien-3,&-ol acetate was hydrolysed and the 
free sterol purified by TLC in system C. 
Fetal horse gonadal tissue (3.5 g from an 
8-9 month fetus) was homogenised in 10 ml of 
phosphate buffer (0.1 mol/l, pH 7.4) using a glass 
homogeniser with a motor driven teflon pestle, 
250 rpm, for 1 min. The buffer also contained 
nicotinamide (3 mmol/l), magnesium chloride 
(5 mmol/l) and reduced glutathione (7.5 mmol/l). 
A portion of the homogenate (5 ml) was in- 
cubated at 37°C for 1 h in air with 5,7-[la&- 
(n)-‘Hlcholestadien-3P-ol (74 kBq, 0.8 pg) in pro- 
pylene glycol (50 pl), 3fl-hydroxy-5,7-androsta- 
dien-17-one (15 pmol/l), 3,&hydroxy-5,7-preg- 
nadien-20-one (15 pmol/l), NADPH (0.7 mmol/l), 
glucose 6-phosphate (6 mmol/l) and glucose-6- 
phosphate dehydrogenase (0.2 unit/ml). 
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A further 5 ml of the homogenate was incubated 
at 37°C for 1 h in air with 3fl-hydroxy-5,7-[4-‘“Cl- 
pregnadien-20-one (18.5 kBq, 2.9 ,ug) in propylene 
glycol (50~1), 3&hydroxy-5,7-androstadien-17- 
one (15 pmol/l), NADPH (0.7 mmol/l), glucose 
6-phosphate (6 mmol/l) and glucose-6-phosphate 
dehydrogenase (0.2 unit/ml). 
The incubations were extracted as previously 
described [4,5] and the extracts separated into 
sterol and steroid fractions by TLC in system B. 
The sterol fraction was acetylated and rechromato- 
graphed in system D giving cholesterol acetate 
which was purified further by HPLC using 
methanol, flow rate 2 ml/min, as the mobile 
phase. The steroid fraction was acetylated, carrier 
steroids 3&hydroxy-5,7-pregnadien-20-one, 3,& 
hydroxy-5,7-androstadien-17-one, pregnenolone 
and dehydroepiandrosterone (DHA) acetates 
(0.15 pmol of each) were added, and the mixture 
chromatographed in system D giving a fraction 
containing these four steroids. This mixture was 
resolved into its components by HPLC using 10% 
water in methanol, flow rate 1 ml/min, as the 
mobile phase. 
Carrier steroid (150 pmol) was added to a por- 
tion of the extracts from the final chromatograms 
and crystallised to constant specific activity [4,5]. 
3. RESULTS 
Table 1 shows that, when 5,7-cholestadien-3P-ol 
was incubated with homogenates from two dif- 
ferent horse fetal gonads, cholesterol, pregnenol- 
one, DHA, 3,&hydroxy-5,7-pregnadien-20-one 
and 3&hydroxy-5,7-androstadien- 17-one were 
formed. 
Similarly, incubations with 3&hydroxy-5,7- 
[4-‘4C]pregnadien-20-one assubstrate gave 3,&hy- 
droxy-5,7-androstadien-17-one. This was char- 
acterised as its acetate (spec. act. 1070 -t 10 dpm/ 
pmol), 5,7-androstadiene-3fl, 17,&diol 3-acetate 
(spec. act. 1080 f 40 dpm/pmol) and 5,7-andro- 
stadien-3/3,17,&diol diacetate (spec. act. 1040 f 
20 dpm/pmol). With tissue from a second horse, 
the specific activities for the same three com- 
pounds were 648 f 33; 661 + 33 and 669 + 19 
dpm/pmol, respectively. 
The DHA and pregnelone fractions isolated 
from the incubations with 3,&hydroxy-5,7-[4-r4C]- 
pregnadien-20-one were not radioactive. 
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Table 1 
Identification of the steroids produced on incubating 5,7-cholestadien3,&ol with homogenates of fetal horse gonadal 
tissue 
Steroid Derivative formed Specific activitya 
dpm/pmol (SD) 
incubation 
(1) 
Incubation 
(2) 
Cholesterol 
Pregnenolone 
Dehydroepiandrosterone 
3fl-Hydroxy-5,7-pregnadien-20-one 
3~-Hydroxy-5,7-androstadien-17-one 
cholesterol acetate 
5-pregnene-3,&,2O&diol diacetate 
androstenedione 
3&hydroxy-5,7-pregnadien-20-one 
acetate 
5,7-pregnadiene-3~,2~-dial 3-acetate 
5,7-pregnadiene-3~,2~-dial diacetate 
3,&hydroxy-5,7-androstadien-17-one 
acetate 
5,7-androstadiene-3/3,17&diol 
3-acetate 
5,7-androstadiene-3fl, 17&diol 
diacetate 
4530 (190) 
4560 ( 90) 
111 ( 2) 
109 ( 4) 
_ 
19.4 ( 1) 
_ 
183 ( 1) 
184 ( 3) 
177 ( 3) 
- 
129 ( 6) 
132 ( 8) 
137 ( 1) 
3950 (100 ) 
3920 ( 50 ) 
30.1 ( 0.7) 
30.7 ( 1.2) 
69 ( 2.2) 
91.7 ( 1.8) 
89.3 ( 2.5) 
84.1 ( 3.5) 
311 ( 7 ) 
303 ( 6 ) 
320 ( 9 ) 
a The specific activities were judged to be constant when three crops agreed to within t- 5%. For brevity only the means 
and SD of the specific activities of each derivative are given 
4, DISCUSSION 
The conversion of 5,7-[lcr,2cu(n)-3H]cholesta- 
dien-3@ol and 3,&hydroxy-5,7-[4-‘4C]pregnadien- 
20-one to 3&hydroxy-5,7_androstadien- 17-one 
supports the proposal that there is a 5,7-diene 
pathway operating in fetal horse gonadal tissue [4]. 
This, with the previous report that the tissue can 
biosynthesise these three compounds from radio- 
active sodium acetate [4,5], suggests that 3,& 
hydroxy-5,7-androstadien-17-one, the proposed 
precursor of equilin, is biosynthesised by the triter- 
pene pathway. 
Squalene - lanosterol -+ 5,7-choIestadien-3,&-of (VI) - cholesterol 
t 
I 
I 
I I 
3/3-hyd!oxy-5,7- pregne)nolone 
pregnadienfo-one (III) I 
I 
I : 
3&hydrtcxy-5,7- deh!dro- 
~drostadien-17-one (IV) epiandrosterone 
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This tissue was also able to transform 5,7-chol- 
estadien-3&ol to cholesterol, pregnenolone and 
DHA, implying that the classical pathway for 
steroid hormone biosynthesis, in which 5,7-chol- 
estadien-3@-ol is reduced to cholesterol, was opera- 
tional in addition to the 5,7-diene pathway. Also, 
since neither pregnenolone nor DHA was a pro- 
duct of the 3~-hydroxy-5,7-pregnadien-20-one in- 
cubations, it appears that they are produced from 
5,7-~holestadien-3~-ol via cholesterol. 
In contrast to these in vitro findings, it has been 
reported that [14CJsqualene was not converted to 
[14C]equilin, on infusion in vivo into the equine 
feto-placental unit [9], implying that 5,7-cholesta- 
dien-3@al, and possibly 3~-hydroxy-5,7-pregna- 
dien-20-one and 3~-hydroxy-5,7-androstadien-17- 
one, are not intermediates in equilin biosynthesis. 
It might be argued that the use of homogenates 
brings into play enzymes to which the precursors 
are not exposed in vivo. Alternatively, infused 
precursors may not fully enter biosynthetic se- 
quences in vivo because of differences in perme- 
ability and pool sizes [9]. These contrasting find- 
ings could be resolved by an in vivo experiment o 
test whether 5,7-cholestadien-3@-01, injected into 
the umbilical circulation of the pregnant mare, is 
converted to the ring B unsaturated estrogens. 
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